Clinical Trial

A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate the efficacy and safety of HRS-5632 in adult participants with elevated Lipoprotein(a) (Lp(a)) at high risk for cardiovascular events.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-09-15; most recent amendment 2026-03-03.
Status change: Recruiting → Active, Not Recruiting 2026-03-03
Status change: Not Yet Recruiting → Recruiting 2025-09-28
Trial Details
NCT Number NCT07185776
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Lipoprotein Disorder
Enrollment 203 participants
Start Date 2025-10-21
Primary Completion 2027-04 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-05